MedTrace Logo

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

NCT01805544 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2017-01-23

No results posted yet for this study

Summary

National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) is associated with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score.

Conditions

  • Venous Thrombosis

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • France

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805544 on ClinicalTrials.gov